Bei Jing Shang Bao·2025-11-19 11:50Core Viewpoint - The announcement of a strategic cooperation agreement between Baili Tianheng and Bank of China Sichuan Branch aims to enhance the company's development in the global biopharmaceutical sector, particularly in antibody-drug conjugates (ADC) and multi-specific antibodies, with a commitment of no less than 8 billion RMB in comprehensive credit support [1][1][1] Group 1 - Baili Tianheng has signed a strategic cooperation agreement with Bank of China Sichuan Branch to establish a long-term comprehensive strategic partnership [1] - The Bank of China Sichuan Branch commits to providing a total of no less than 8 billion RMB in credit support to facilitate Baili Tianheng's development strategy [1] - This agreement is expected to accelerate Baili Tianheng's strategic layout in the forefront of the global biopharmaceutical field and strengthen its leading position in ADC and multi-specific antibody sectors [1] Group 2 - The cooperation is seen as beneficial for both parties to seize new opportunities in the global biopharmaceutical industry, aiming for mutual benefit and common development [1] - The financial support aligns with the company's development plan and the interests of all shareholders [1]